Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The cytochrome bc1 complex, also known as Complex III, is a critical component of the mitochondrial electron transport chain in Plasmodium species. This enzyme complex catalyzes the transfer of electrons from ubiquinol to cytochrome c and is essential for maintaining mitochondrial membrane potential and ATP production in the parasite. It is a validated target for antimalarial therapy, with drugs like atovaquone targeting the Qo site. However, resistance can develop rapidly through mutations. Newer inhibitors target either or both Qo and Qi sites with varying selectivity. Structural studies guide rational drug design efforts to overcome resistance while minimizing toxicity.
Inhibition of electron transfer from ubiquinol to cytochrome c, thereby disrupting ATP synthesis and pyrimidine biosynthesis in the parasite.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytochrome bc1 Complex (Plasmodium) (bc1 Complex).